|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.73 CAD | +0.70% |
|
+0.17% | +10.40% |
| Mar. 22 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
| Mar. 21 | Knight Therapeutics Reports Fourth Quarter Results | MT |
Knight Therapeutics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CAD 328.2 million compared to CAD 293.56 million a year ago. Net loss was CAD 16.84 million compared to CAD 29.89 million a year ago.
Basic loss per share from continuing operations was CAD 0.16 compared to CAD 0.26 a year ago. Diluted loss per share from continuing operations was CAD 0.16 compared to CAD 0.26 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +10.40% | 424M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
KNIGHT THERAPEUTICS INC. 
